| Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes A Äbelö, TB Andersson, M Antonsson, AK Naudot, I Skånberg, L Weidolf Drug Metabolism and Disposition 28 (8), 966-972, 2000 | 491 | 2000 |
| Structure− brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids M Fridén, S Winiwarter, G Jerndal, O Bengtsson, H Wan, U Bredberg, ... Journal of medicinal chemistry 52 (20), 6233-6243, 2009 | 228 | 2009 |
| In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids M Friden, A Gupta, M Antonsson, U Bredberg, M Hammarlund-Udenaes Drug metabolism and disposition 35 (9), 1711-1719, 2007 | 208 | 2007 |
| Activation of the GABAB receptor inhibits transient lower esophageal sphincter relaxations in dogs A Lehmann, M Antonsson, M Bremner-Danielsen, M Flärdh, ... Gastroenterology 117 (5), 1147-1154, 1999 | 168 | 1999 |
| Development of a high-throughput brain slice method for studying drug distribution in the central nervous system M Friden, F Ducrozet, B Middleton, M Antonsson, U Bredberg, ... Drug metabolism and disposition 37 (6), 1226-1233, 2009 | 146 | 2009 |
| In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms H Chen, S Winiwarter, M Fridén, M Antonsson, O Engkvist Journal of Molecular Graphics and Modelling 29 (8), 985-995, 2011 | 67 | 2011 |
| Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (RO) T Andersson, E Bredberg, M Sunzel, M Antonsson, L Weidolf Gastroenterology 4 (118), A1210, 2000 | 63 | 2000 |
| Discovery of (3-(4-(2-oxa-6-azaspiro [3.3] heptan-6-ylmethyl) phenoxy) azetidin-1-yl)(5-(4-methoxyphenyl)-1, 3, 4-oxadiazol-2-yl) methanone (AZD1979), a melanin concentrating … A Johansson, C Lofberg, M Antonsson, S von Unge, MA Hayes, R Judkins, ... Journal of Medicinal Chemistry 59 (6), 2497-2511, 2016 | 55 | 2016 |
| Drug metabolism and pharmacokinetic strategies for oligonucleotide-and mRNA-based drug development S Andersson, M Antonsson, M Elebring, R Jansson-Löfmark, L Weidolf Drug discovery today 23 (10), 1733-1745, 2018 | 54 | 2018 |
| (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action A Lehmann, M Antonsson, AA Holmberg, LA Blackshaw, L Brändén, ... Journal of Pharmacology and Experimental Therapeutics 331 (2), 504-512, 2009 | 49 | 2009 |
| Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain M Fridén, M Wennerberg, M Antonsson, M Sandberg-Ställ, L Farde, ... EJNMMI research 4, 1-8, 2014 | 36 | 2014 |
| A modeling approach for compounds affecting body composition P Gennemark, R Jansson-Löfmark, G Hyberg, M Wigstrand, D Kakol-Palm, ... Journal of pharmacokinetics and pharmacodynamics 40, 651-667, 2013 | 21 | 2013 |
| Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog M Nordström, T Abrahamsson, M Ervik, E Forshult, CG Regårdh Journal of Pharmacology and Experimental Therapeutics 266 (1), 147-152, 1993 | 21 | 1993 |
| Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease AT Plowright, K Nilsson, M Antonsson, K Amin, J Broddefalk, J Jensen, ... Journal of Medicinal Chemistry 56 (1), 220-240, 2013 | 20 | 2013 |
| Effects of a novel potent melanin‐concentrating hormone receptor 1 antagonist, AZD1979, on body weight homeostasis in mice and dogs K Ploj, L Benthem, D Kakol‐Palm, P Gennemark, L Andersson, M Bjursell, ... British Journal of Pharmacology 173 (18), 2739-2751, 2016 | 16 | 2016 |
| Translational modeling to guide study design and dose choice in obesity exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist P Gennemark, M Trägårdh, D Lindén, K Ploj, A Johansson, A Turnbull, ... CPT: Pharmacometrics & Systems Pharmacology 6 (7), 458-468, 2017 | 7 | 2017 |
| Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans E Ericson, L Bergenholm, AC Andréasson, CI Dix, J Knöchel, SF Hansson, ... Hepatology Communications 6 (10), 2689-2701, 2022 | 3 | 2022 |
| A biocompatible chemically modified mRNA drives sustained VEGF-A protein production, human endothelial angiogenesis and epicardial progenitor expansion, and reduces infarct … L Carlsson, CY Yen, YP Wang, RH Lin, AH Lo, CH Chen, J Clarke, ... Circulation 134 (suppl_1), A15533-A15533, 2016 | 3 | 2016 |
| Different in vitro and in vivo profiles of substituted 3‐aminopropylphosphinate and 3‐aminopropyl(methyl)phosphinate GABAB receptor agonists as inhibitors of … A Lehmann, M Antonsson, A Aurell‐Holmberg, LA Blackshaw, L Brändén, ... British journal of pharmacology 165 (6), 1757-1772, 2012 | 3 | 2012 |
| AZD3355, a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action A Lehmann, M Antonsson, AA Holmberg, LA Blackshaw, L Branden, ... Journal of Pharmacology and Experimental Therapeutics, 2009 | 3 | 2009 |
